82 FR 47538 - National Institute of General Medical Sciences; Notice of Closed Meetings

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 82, Issue 196 (October 12, 2017)

Page Range		47538-47538
FR Document		2017-21990

Federal Register, Volume 82 Issue 196 (Thursday, October 12, 2017)

[Federal Register Volume 82, Number 196 (Thursday, October 12, 2017)]
[Notices]
[Page 47538]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2017-21990]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of General Medical Sciences; Notice of Closed 
Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of General Medical 
Sciences Special Emphasis Panel; Review of Support of Competitive 
Research (SCORE) Award Applications.
    Date: November 8, 2017.
    Time: 8:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Courtyard by Marriott Chevy Chase, 5520 Wisconsin Avenue, 
Chevy Chase, MD 20815.
    Contact Person: Manas Chattopadhyay, Ph.D., Scientific Review 
Officer, Office of Scientific Review, National Institute of General 
Medical Sciences, National Institutes of Health, Building 45, Room 
3An12N, 45 Center Drive, Bethesda, MD 20892, 301-827-5320, 
manasc@mail.nih.gov.

    Name of Committee: National Institute of General Medical 
Sciences Special Emphasis Panel; Review of NIH Pathway to 
Independence Award K99/R00 Applications.
    Date: November 16, 2017.
    Time: 8:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Hilton Garden Inn Bethesda, 7301 Waverly Street, 
Bethesda, MD 20814.
    Contact Person: Robert Horowits, Ph.D., Scientific Review 
Officer, National Institute of General Medical Sciences, National 
Institutes of Health, 45 Center Drive, Room 3An.18, Bethesda, MD 
20892-6200, 301-594-6904, horowitr@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.375, 
Minority Biomedical Research Support; 93.821, Cell Biology and 
Biophysics Research; 93.859, Pharmacology, Physiology, and 
Biological Chemistry Research; 93.862, Genetics and Developmental 
Biology Research; 93.88, Minority Access to Research Careers; 93.96, 
Special Minority Initiatives; 93.859, Biomedical Research and 
Research Training, National Institutes of Health, HHS)

    Dated: October 5, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-21990 Filed 10-11-17; 8:45 am]
 BILLING CODE 4140-01-P

47538 Federal Register / Vol. 82, No. 196 / Thursday, October 12, 2017 / Notices

SUPPLEMENTARY INFORMATION: The results in production of noninfectious Panel; Review of Support of Competitive
following represents the intellectual VLPs that generate protective Research (SCORE) Award Applications.
property is to be licensed under the neutralizing antibodies against ZIKA Date: November 8, 2017.
prospective agreement: HHS Ref. No. E– infection. The vaccine, which is based Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
181–2016/0, including provisional on a similar vaccine developed for the applications.
patent applications 62/396,613 filed related West Nile virus, is currently Place: Courtyard by Marriott Chevy Chase,
September 19, 2016 entitled ‘‘Zika Virus undergoing clinical trial evaluation. The 5520 Wisconsin Avenue, Chevy Chase, MD
Vaccines’’, and all continuing U.S. and subject invention has been advertised in 20815.
foreign patents/patent applications for the Federal Register and published on Contact Person: Manas Chattopadhyay,
the technology family, to PaxVax Inc. 12 December 2016. Ph.D., Scientific Review Officer, Office of
All rights in these inventions have This notice is made in accordance Scientific Review, National Institute of
been assigned to the Government of the General Medical Sciences, National Institutes
with 35 U.S.C. 209 and 37 CFR part 404.
United States of America. of Health, Building 45, Room 3An12N, 45
The prospective Exclusive Patent Center Drive, Bethesda, MD 20892, 301–827–
The prospective Exclusive Patent License will be royalty bearing and may
License territory may be worldwide and 5320, manasc@mail.nih.gov.
be granted unless within thirty (30) days Name of Committee: National Institute of
the field of use may be limited to: from the date of this published notice,
‘‘Development and use of DNA-based General Medical Sciences Special Emphasis
the NIAID receives written evidence and Panel; Review of NIH Pathway to
vaccines expressing virus-like particle argument that establishes that the grant Independence Award K99/R00 Applications.
antigens comprising Zika virus of the license would not be consistent Date: November 16, 2017.
membrane and/or envelope proteins for with the requirements of 35 U.S.C. 209 Time: 8:00 a.m. to 5:00 p.m.
prevention of Zika virus infection in Agenda: To review and evaluate grant
and 37 CFR part 404.
humans.’’ applications.
Since 2015, Zika virus (ZIKV) Complete applications for a license in
Place: Hilton Garden Inn Bethesda, 7301
outbreaks have had a significant effect the prospective field of use that are Waverly Street, Bethesda, MD 20814.
on global public health. The mosquito- timely filed in response to this notice Contact Person: Robert Horowits, Ph.D.,
borne disease, which causes several will be treated as objections to the grant Scientific Review Officer, National Institute
congenital abnormalities in the of the contemplated Exclusive Patent of General Medical Sciences, National
developing fetus, as well as other License. Comments and objections Institutes of Health, 45 Center Drive, Room
submitted to this notice will not be 3An.18, Bethesda, MD 20892–6200, 301–
neurological disorders in infected
made available for public inspection 594–6904, horowitr@mail.nih.gov.
individuals has no approved vaccine to
treat or prevent infection. To address and, to the extent permitted by law, will (Catalogue of Federal Domestic Assistance
not be released under the Freedom of Program Nos. 93.375, Minority Biomedical
this critical need, several approaches are Research Support; 93.821, Cell Biology and
being explored for a vaccine against Information Act, 5 U.S.C. 552.
Biophysics Research; 93.859, Pharmacology,
ZIKV infection in priority populations Dated: October 5, 2017. Physiology, and Biological Chemistry
including women of child-bearing age Suzanne Frisbie, Research; 93.862, Genetics and
and their partners. Deputy Director, Technology Transfer and Developmental Biology Research; 93.88,
Many entities, governmental, Intellectual Property Office, National Institute Minority Access to Research Careers; 93.96,
academic, and commercial, are actively of Allergy and Infectious Diseases. Special Minority Initiatives; 93.859,
pursuing development of ZIKV vaccines Biomedical Research and Research Training,
[FR Doc. 2017–21986 Filed 10–11–17; 8:45 am]
each using a different approach to National Institutes of Health, HHS)
BILLING CODE 4140–01–P
address this public health need. The Dated: October 5, 2017.
U.S. Government is coordinating its Melanie J. Pantoja,
vaccine development response to ZIKV DEPARTMENT OF HEALTH AND Program Analyst, Office of Federal Advisory
and has published this plan at https:// HUMAN SERVICES Committee Policy.
www.phe.gov/Preparedness/planning/ [FR Doc. 2017–21990 Filed 10–11–17; 8:45 am]
Pages/zika-white-paper.aspx. National Institutes of Health BILLING CODE 4140–01–P
Vaccine development approaches for
ZIKV include but are not limited to National Institute of General Medical
inactivated virus (dead virus), live Sciences; Notice of Closed Meetings DEPARTMENT OF HEALTH AND
attenuated virus (weakened virus), HUMAN SERVICES
recombinant viral vectors (weakened Pursuant to section 10(d) of the
virus with target genes added), and Federal Advisory Committee Act, as National Institutes of Health
subunit (portion of a virus) as well as amended, notice is hereby given of the
mRNA- and DNA-based (gene-targeted). following meetings. National Institute on Deafness and
These various strategies provide The meetings will be closed to the Other Communication Disorders;
multiple redundancies, expanded public in accordance with the Notice of Meeting
choice, and ensure short and long term provisions set forth in sections
maximal benefits to the public. 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Pursuant to section 10(d) of the
The subject invention relates to the as amended. The grant applications and Federal Advisory Committee Act, as
use of nucleic acid molecules encoding the discussions could disclose amended, notice is hereby given of a
confidential trade secrets or commercial meeting of the Board of Scientific
asabaliauskas on DSKBBXCHB2PROD with NOTICES

Zika virus (ZIKV) proteins that when
introduced in a cell produces property such as patentable material, Counselors, NIDCD.
noninfectious virus-like particles (VLPs) and personal information concerning The meeting will be open to the
capable of eliciting a protective immune individuals associated with the grant public as indicated below, with
response against viral infection. More applications, the disclosure of which attendance limited to space available.
specifically, the subject vaccine is a would constitute a clearly unwarranted Individuals who plan to attend and
DNA-based candidate encoding a invasion of personal privacy. need special assistance, such as sign
polypeptide of a ZIKV membrane and Name of Committee: National Institute of language interpretation or other
envelope proteins that when expressed General Medical Sciences Special Emphasis reasonable accommodations, should

VerDate Sep<11>2014 22:35 Oct 11, 2017 Jkt 244001 PO 00000 Frm 00093 Fmt 4703 Sfmt 4703 E:\FR\FM\12OCN1.SGM 12OCN1

Document Created: 2018-10-25 10:05:24
Document Modified: 2018-10-25 10:05:24

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Dates		November 8, 2017.
FR Citation		82 FR 47538

82 FR 47538 - National Institute of General Medical Sciences; Notice of Closed Meetings

DEPARTMENT OF HEALTH AND HUMAN SERVICESNational Institutes of Health

Federal Register Volume 82, Issue 196 (October 12, 2017)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health